Kraj: Kanada
Język: angielski
Źródło: Health Canada
DOXORUBICIN HYDROCHLORIDE
PFIZER CANADA ULC
L01DB01
DOXORUBICIN
150MG
POWDER FOR SOLUTION
DOXORUBICIN HYDROCHLORIDE 150MG
INTRAVENOUS
150MG/VIAL
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0110825004; AHFS:
CANCELLED POST MARKET
2006-08-02
PRODUCT MONOGRAPH ADRIAMYCIN * RDF * (doxorubicin hydrochloride for Injection USP) 10 mg, 50 mg and 150 mg Vials Antineoplastic agent Pfizer Canada Inc Date of Preparation: 17,300 Trans-Canada Highway 11 September 2003 Kirkland, Quebec H9J 2M5 Control No. 086543 * TM Pharmacia Enterprises S.A. Pfizer Canada Inc, Licensee © Pfizer Canada Inc 2003 2 NAME OF DRUG ADRIAMYCIN * RDF * Doxorubicin Hydrochloride for Injection USP 10 mg, 50 mg and 150 mg Vials CAUTION: ADRIAMYCIN (DOXORUBICIN HYDROCHLORIDE) IS A POTENT DRUG AND SHOULD BE USED ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPY DRUGS (SEE WARNINGS AND PRECAUTIONS). BLOOD COUNTS AND HEPATIC FUNCTION TESTS SHOULD BE PERFORMED REGULARLY. BECAUSE OF THE EXPERIENCE WITH CARDIAC TOXICITY, IT IS NOT RECOMMENDED TO EXCEED A TOTAL DOSE OF ADRIAMYCIN 550 MG/M 2 WITH THE 21 DAY REGIMEN AND 700 MG/M 2 WITH THE WEEKLY REGIMEN. CARDIAC MONITORING IS ADVISED IN THOSE PATIENTS WHO HAVE RECEIVED MEDIASTINAL RADIOTHERAPY, OTHER ANTHRACYCLINE OR ANTHRACENE THERAPY, WITH PRE-EXISTING CARDIAC DISEASE, OR WHO HAVE RECEIVED PRIOR ADRIAMYCIN CUMULATIVE DOSES EXCEEDING 400 MG/M 2 WITH THE 21 DAY REGIMEN AND 550 MG/M 2 UTILIZING THE WEEKLY REGIMEN. THERAPEUTIC CLASSIFICATION Antineoplastic Agent CLINICAL PHARMACOLOGY Though not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. Animal studies have shown activity in a wide spectrum of experimental tumours, immunosuppression, carcinogenic properties in rodents, induction of a variety of toxic effects, including delayed and progressive cardiac toxicity, myelosuppression in all species and atrophy of testes in rats and dogs. 3 Pharmacokinetic studies show that the intravenous administration of normal or radiolabelled ADRIAMYCIN (doxorubicin hy Przeczytaj cały dokument